Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2020; 26(31): 4579-4588
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4579
COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract
Michail Galanopoulos, Filippos Gkeros, Aris Doukatas, Grigorios Karianakis, Christos Pontas, Nikolaos Tsoukalas, Nikos Viazis, Christos Liatsos, Gerassimos J Mantzaris
Michail Galanopoulos, Christos Liatsos, Department of Gastroenterology, 401 General Military Hospital of Athens, Athens 11525, Attiki, Greece
Filippos Gkeros, Christos Pontas, Nikos Viazis, Gerassimos J Mantzaris, Department of Gastroenterology, Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Athens 10676, Attiki, Greece
Aris Doukatas, Grigorios Karianakis, Medical Office of Hellenic Army General Staff, 401 General Military Hospital of Athens, Athens 11525, Attiki, Greece
Nikolaos Tsoukalas, Department of Oncology, 401 General Military Hospital of Athens, Athens 11525, Attiki, Greece
Author contributions: Galanopoulos M designed the review; Galanopoulos M, Gkeros F, Doukatas A, Karianakis G and Pontas C analyzed and interpreted the data; Tsoukalas N, Viazis N and Liatsos C drafted the manuscript; Mantzaris GJ critically revised the paper.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Michail Galanopoulos, FEBG, MD, PhD, Doctor, Department of Gastroenterology, 401 General Military Hospital of Athens, 138 Mesogeion Avenue and Katechaki Street, Athens 11525, Attiki, Greece. galanopoulosdr@gmail.com
Received: May 6, 2020
Peer-review started: May 6, 2020
First decision: May 26, 2020
Revised: June 2, 2020
Accepted: August 12, 2020
Article in press: August 12, 2020
Published online: August 21, 2020
Processing time: 106 Days and 16.3 Hours
Abstract

The pandemic of coronavirus disease 2019 (COVID-19), caused by a newly identified β-coronavirus (SARS-CoV-2) has emerged as a dire health problem, causing a massive crisis for global health. Primary method of transmission was firstly thought to be animal to human transmission. However, it has been observed that the virus is transmitted from human to human via respiratory droplets. Interestingly, SARS-CoV-2 ribonucleic acid (RNA) has been isolated from patient stools, suggesting a possible gastrointestinal (GI) involvement. Most commonly reported clinical manifestations are fever, fatigue and dry cough. Interestingly, a small percentage of patients experience GI symptoms with the most common being anorexia, diarrhea, nausea and vomiting. The presence of viral RNA in stools is also common and fecal tests can be positive even after negative respiratory samples. The exact incidence of digestive symptoms is a matter of debate. The distribution of Angiotensin converting enzyme type 2 receptors in multiple organs in the body provides a possible explanation for the digestive symptoms’ mechanism. Cases with solely GI symptoms have been reported in both adults and children. Viral RNA has also been detected in stool and blood samples, indicating the possibility of liver damage, which has been reported in COVID-19 patients. The presence of chronic liver disease appears to be a risk factor for severe complications and a poorer prognosis, however data from these cases is lacking. The aim of this review is firstly, to briefly update what is known about the origin and the transmission of SARS-CoV-2, but mainly to focus on the manifestations of the GI tract and their pathophysiological background, so that physicians on the one hand, not to underestimate or disregard digestive symptoms due to the small number of patients exhibiting exclusively this symptomatology and on the other, to have SARS-CoV-2 on their mind when the “gastroenteritis” type symptoms predominate.

Keywords: SARS-CoV-2; COVID-19; COVID-19 gastrointestinal manifestations; Gastrointestinal tract; COVID-19 on chronic liver diseases; ACE2 receptors and COVID-19; COVID-19 and gastrointestinal pathophysiology

Core tip: Although respiratory transmission and symptoms are still the primary route and expression of coronavirus disease 2019 (COVID-19), the gastrointestinal system could be an alternative or additional way for COVID-19 to be transmitted and manifested, most likely due to the presence of Angiotensin converting enzyme type 2 receptors which are observed throughout its length. The main aim of this article is mainly to focus on the manifestations of the gastrointestinal tract and their pathophysiological background, so that physicians on the one hand, not to underestimate or disregard digestive symptoms due to the small number of patients exhibiting exclusively this symptomatology and, on the other, to have severe acute respiratory syndrome coronavirus 2 on their mind when the “gastroenteritis” type symptoms predominate.